3G8I | pdb_00003g8i

Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes

No genome alignments are available

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.